Preclinical Activity of the Oral Proteasome Inhibitor MLN9708 in Myeloma Bone Disease

Abstract

Given favorable data on pharmacologic properties and emerging clinical safety profile of MLN9708, it is conceivable that this proteasome inhibitor may achieve bone beneficial effects in addition to its antimyeloma activity in patients with myeloma.